Engineering T cell response to cancer antigens by choice of focal therapeutic conditions
Focal thermal therapy (Heat), cryosurgery (Cryo) and irreversible electroporation (IRE) are increasingly used to treat cancer. However, local recurrence and systemic spread are persistent negative outcomes. Nevertheless, emerging work with immunotherapies (i.e., checkpoint blockade or dendritic cell...
Saved in:
Published in | International journal of hyperthermia Vol. 36; no. 1; pp. 130 - 138 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Taylor & Francis
01.01.2019
Taylor & Francis Group |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Focal thermal therapy (Heat), cryosurgery (Cryo) and irreversible electroporation (IRE) are increasingly used to treat cancer. However, local recurrence and systemic spread are persistent negative outcomes. Nevertheless, emerging work with immunotherapies (i.e., checkpoint blockade or dendritic cell (DC) vaccination) in concert with focal therapies may improve outcomes. To understand the role of focal therapy in priming the immune system for immunotherapy, an in vitro model of T cell response after exposure to B16 melanoma cell lysates after lethal exposures was designed. Exposure included: Heat (50 °C, 30 min), Cryo (−80 °C, 30 min) and IRE (1250 V/cm, 99 pulses, 50 µs pulses with 1 Hz intervals). After viability assessment (CCK-8 assay), cell lysates were collected and assessed for protein release (BCA assay), protein denaturation (FTIR-spectroscopy), TRP-2 antigen release (western blot), and T cell activation (antigen-specific CD8 T cell proliferation). Results showed IRE released the most protein and antigen (TRP-2), followed by Cryo and Heat. In contrast, Cryo released the most native (not denatured) protein, compared to IRE and Heat. Finally, IRE dramatically outperformed both Cryo and Heat in T cell activation while Cryo modestly outperformed Heat. This study demonstrates that despite all focal therapies ability to destroy cells, the 'quantity' (i.e., amount) and 'quality' (i.e., molecular state) of tumor protein (including antigen) released can dramatically change the ensuing priming of the immune system. This suggests protein-based metrics whereby focal therapies can be designed to prime the immune system in concert with immunotherapies to eventually achieve improved and durable cancer treatment in vivo. |
---|---|
AbstractList | Focal thermal therapy (Heat), cryosurgery (Cryo) and irreversible electroporation (IRE) are increasingly used to treat cancer. However, local recurrence and systemic spread are persistent negative outcomes. Nevertheless, emerging work with immunotherapies (i.e., checkpoint blockade or dendritic cell (DC) vaccination) in concert with focal therapies may improve outcomes. To understand the role of focal therapy in priming the immune system for immunotherapy, an in vitro model of T cell response after exposure to B16 melanoma cell lysates after lethal exposures was designed. Exposure included: Heat (50 °C, 30 min), Cryo (-80 °C, 30 min) and IRE (1250 V/cm, 99 pulses, 50 µs pulses with 1 Hz intervals). After viability assessment (CCK-8 assay), cell lysates were collected and assessed for protein release (BCA assay), protein denaturation (FTIR-spectroscopy), TRP-2 antigen release (western blot), and T cell activation (antigen-specific CD8 T cell proliferation). Results showed IRE released the most protein and antigen (TRP-2), followed by Cryo and Heat. In contrast, Cryo released the most native (not denatured) protein, compared to IRE and Heat. Finally, IRE dramatically outperformed both Cryo and Heat in T cell activation while Cryo modestly outperformed Heat. This study demonstrates that despite all focal therapies ability to destroy cells, the 'quantity' (i.e., amount) and 'quality' (i.e., molecular state) of tumor protein (including antigen) released can dramatically change the ensuing priming of the immune system. This suggests protein-based metrics whereby focal therapies can be designed to prime the immune system in concert with immunotherapies to eventually achieve improved and durable cancer treatment in vivo. Focal thermal therapy (Heat), cryosurgery (Cryo) and irreversible electroporation (IRE) are increasingly used to treat cancer. However, local recurrence and systemic spread are persistent negative outcomes. Nevertheless, emerging work with immunotherapies (i.e., checkpoint blockade or dendritic cell (DC) vaccination) in concert with focal therapies may improve outcomes. To understand the role of focal therapy in priming the immune system for immunotherapy, an in vitro model of T cell response after exposure to B16 melanoma cell lysates after lethal exposures was designed. Exposure included: Heat (50 °C, 30 min), Cryo (−80 °C, 30 min) and IRE (1250 V/cm, 99 pulses, 50 µs pulses with 1 Hz intervals). After viability assessment (CCK-8 assay), cell lysates were collected and assessed for protein release (BCA assay), protein denaturation (FTIR-spectroscopy), TRP-2 antigen release (western blot), and T cell activation (antigen-specific CD8 T cell proliferation). Results showed IRE released the most protein and antigen (TRP-2), followed by Cryo and Heat. In contrast, Cryo released the most native (not denatured) protein, compared to IRE and Heat. Finally, IRE dramatically outperformed both Cryo and Heat in T cell activation while Cryo modestly outperformed Heat. This study demonstrates that despite all focal therapies ability to destroy cells, the 'quantity' (i.e., amount) and 'quality' (i.e., molecular state) of tumor protein (including antigen) released can dramatically change the ensuing priming of the immune system. This suggests protein-based metrics whereby focal therapies can be designed to prime the immune system in concert with immunotherapies to eventually achieve improved and durable cancer treatment in vivo. |
Author | O'Flanagan, Stephen Shimizu, Yoji Bischof, John C Lam, Tiffany Pelaez, Francisco Burbach, Brandon J Shao, Qi Roy, Priyatanu Azarin, Samira M |
Author_xml | – sequence: 1 givenname: Qi orcidid: 0000-0002-8190-1067 surname: Shao fullname: Shao, Qi organization: Institute for Engineering in Medicine, University of Minnesota – sequence: 2 givenname: Stephen surname: O'Flanagan fullname: O'Flanagan, Stephen organization: Department of Laboratory Medicine and Pathology and Center for Immunology, University of Minnesota – sequence: 3 givenname: Tiffany surname: Lam fullname: Lam, Tiffany organization: Department of Chemical Engineering and Materials Science, University of Minnesota – sequence: 4 givenname: Priyatanu surname: Roy fullname: Roy, Priyatanu organization: Department of Mechanical Engineering, University of Minnesota – sequence: 5 givenname: Francisco surname: Pelaez fullname: Pelaez, Francisco organization: Department of Chemical Engineering and Materials Science, University of Minnesota – sequence: 6 givenname: Brandon J surname: Burbach fullname: Burbach, Brandon J organization: Department of Laboratory Medicine and Pathology and Center for Immunology, University of Minnesota – sequence: 7 givenname: Samira M surname: Azarin fullname: Azarin, Samira M organization: Department of Chemical Engineering and Materials Science, University of Minnesota – sequence: 8 givenname: Yoji surname: Shimizu fullname: Shimizu, Yoji organization: Department of Laboratory Medicine and Pathology and Center for Immunology, University of Minnesota – sequence: 9 givenname: John C surname: Bischof fullname: Bischof, John C email: bischof@umn.edu organization: Department of Biomedical Engineering, University of Minnesota |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30676126$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU1vEzEQhi1URNPCTwD5yGWDvf7cG6gqUKkSlyJxs2a949TVxg72Rij_HoekPXKyZD3vvKN5rshFygkJec_ZmjPLPrFeK22EXveM2zVXYuiVeEVWXGrZKa7MBVkdme4IXZKrWp8YY1L15g25FEwbzXu9Ir9u0yYmxBLThj5Qj_NMC9ZdThXpkqmH5LFQSEvcYKp0PFD_mKNHmgMN2cNMl0cssMP9Ej31OU1xiS39lrwOMFd8d36vyc-vtw8337v7H9_ubr7cd16aYen4qMFwEMpORgTUk9fSWA-AxkJAb5BNg-f9wIL21qIdpVdSDKOW_ci9FNfk7jR3yvDkdiVuoRxchuj-feSycVDaajO60GOQ2K4AwKQdcFQAkg-tFIVVdmizPp5m7Ur-vce6uG2sx5NAwryvrudmaNsJYxqqTqgvudaC4aWaM3cU5J4FuaMgdxbUch_OFftxi9NL6tlIAz6fgJhCLlv4k8s8uQUOcy6hNBuxOvH_jr_pzaHA |
CitedBy_id | crossref_primary_10_1038_s41467_021_24132_6 crossref_primary_10_3390_cancers14246254 crossref_primary_10_3390_cancers14122876 crossref_primary_10_3390_vaccines10111942 crossref_primary_10_2147_JHC_S426442 crossref_primary_10_3390_ijms24087344 crossref_primary_10_3389_fimmu_2022_930461 crossref_primary_10_3389_fimmu_2024_1352821 crossref_primary_10_1007_s10439_019_02445_4 crossref_primary_10_3390_bioengineering9090474 crossref_primary_10_1002_adma_202310856 crossref_primary_10_1016_j_jvir_2019_10_015 crossref_primary_10_1007_s00270_020_02564_9 crossref_primary_10_3389_fonc_2023_1153066 crossref_primary_10_3389_fonc_2020_00843 crossref_primary_10_1109_TUFFC_2021_3078094 crossref_primary_10_1053_j_seminoncol_2021_02_004 crossref_primary_10_1016_j_bbadis_2024_167262 crossref_primary_10_1080_02656736_2023_2244206 crossref_primary_10_3389_fimmu_2021_695150 crossref_primary_10_1136_jitc_2022_006133 crossref_primary_10_1016_j_bioelechem_2021_107886 crossref_primary_10_3389_fimmu_2019_02283 crossref_primary_10_1089_bioe_2019_0029 crossref_primary_10_1016_j_heliyon_2023_e23551 crossref_primary_10_1016_j_cryobiol_2023_104844 crossref_primary_10_1016_j_jvir_2023_06_037 crossref_primary_10_3390_mi12030296 crossref_primary_10_3390_life14020217 crossref_primary_10_1038_s41598_019_53974_w crossref_primary_10_1016_j_tvir_2020_100675 crossref_primary_10_3389_fonc_2024_1323070 crossref_primary_10_1016_j_jimed_2023_07_005 crossref_primary_10_1080_02656736_2023_2263672 crossref_primary_10_3390_ijms23169445 crossref_primary_10_1148_radiol_2020192190 crossref_primary_10_1148_radiol_232365 crossref_primary_10_3389_fimmu_2023_1094009 crossref_primary_10_3390_cancers13153902 crossref_primary_10_1055_s_0043_1777845 crossref_primary_10_1039_D3NR04362B crossref_primary_10_1016_j_copbio_2020_01_006 crossref_primary_10_1038_s41598_021_89661_y crossref_primary_10_1016_j_hpb_2021_08_938 crossref_primary_10_3389_fimmu_2021_811726 crossref_primary_10_1007_s12010_023_04760_y crossref_primary_10_1080_2162402X_2019_1652532 crossref_primary_10_3389_fimmu_2021_617365 crossref_primary_10_3389_fonc_2020_01235 crossref_primary_10_1115_1_4053199 crossref_primary_10_3389_fonc_2021_681629 crossref_primary_10_3390_curroncol30050365 crossref_primary_10_1007_s00270_020_02736_7 crossref_primary_10_1007_s11912_021_01057_3 crossref_primary_10_1146_annurev_bioeng_073123_022334 crossref_primary_10_3389_fonc_2022_853779 crossref_primary_10_3390_biomedicines10020450 crossref_primary_10_1080_2162402X_2021_1897295 crossref_primary_10_1016_j_hpb_2021_12_014 crossref_primary_10_1038_s41598_023_34919_w crossref_primary_10_1080_02656736_2020_1768299 crossref_primary_10_1038_s41467_023_36045_7 crossref_primary_10_3390_ijms241411434 crossref_primary_10_1002_jso_27085 crossref_primary_10_1080_02656736_2020_1778800 crossref_primary_10_2147_CMAR_S342527 crossref_primary_10_1016_j_ymthe_2023_01_017 crossref_primary_10_3390_cancers11121850 |
Cites_doi | 10.1158/1078-0432.CCR-04-2422 10.1038/nprot.2015.024 10.1038/nrc3672 10.1007/s10439-017-1932-3 10.1158/1078-0432.CCR-09-0110 10.1148/radiol.13120249 10.1016/j.bbabio.2007.06.004 10.1007/978-3-319-55113-5_17 10.1038/nrurol.2010.142 10.1115/1.4039375 10.1016/j.canlet.2008.05.026 10.1038/sj.bjc.6603341 10.1038/nri1372 10.1016/j.semcancer.2007.06.008 10.1080/02656730500271692 10.1016/bs.ai.2015.12.004 10.1073/pnas.0915174107 10.1245/s10434-009-0846-1 10.1016/j.jvir.2014.01.028 10.4049/jimmunol.179.11.7577 10.1109/TBME.2014.2314357 10.1007/s13277-015-4126-3 10.4049/jimmunol.157.2.617 10.2214/ajr.174.2.1740323 10.1007/s00270-007-9208-1 10.1016/j.cryobiol.2008.10.126 10.4049/jimmunol.1300107 10.1016/j.bbamem.2013.01.014 10.7717/peerj.2810 10.1016/j.immuni.2013.07.012 10.4049/jimmunol.152.8.3884 10.1016/S0140-6736(10)62307-0 10.1038/srep27136 10.1016/j.coi.2013.02.009 10.1016/j.cryobiol.2016.09.063 10.1172/jci.insight.90521 10.1080/02656730310001637343 10.1038/nature10673 10.1080/02656730902976807 10.1038/nri3339 10.1114/B:ABME.0000042226.97347.de 10.1148/radiol.10081634 10.1016/j.diii.2018.02.002 10.1021/mp300505w 10.1158/0008-5472.CAN-06-0206 10.1109/TBME.2014.2367543 10.1038/sj.jid.5700777 10.1016/j.vaccine.2011.11.080 10.1111/j.1464-410X.2005.05502.x 10.1158/0008-5472.CAN-11-1782 10.1007/s00262-016-1891-9 10.1016/j.ccell.2018.03.008 10.1016/S1470-2045(15)00007-8 |
ContentType | Journal Article |
Copyright | 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. 2019 |
Copyright_xml | – notice: 2019 The Author(s). Published with license by Taylor & Francis Group, LLC. 2019 |
DBID | 0YH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 DOA |
DOI | 10.1080/02656736.2018.1539253 |
DatabaseName | Taylor & Francis Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: 0YH name: Taylor & Francis (Open access) url: https://www.tandfonline.com sourceTypes: Publisher |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1464-5157 |
EndPage | 138 |
ExternalDocumentID | oai_doaj_org_article_f2ef4e000aa0489eb5aa419e6de38589 10_1080_02656736_2018_1539253 30676126 1539253 |
Genre | Original Articles Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Carl and Janet Kuhrmeyer Chair – fundername: BTG plc – fundername: Dr. Ralph and Marian Falk Medical Research Trust – fundername: Boston Scientific Corporation – fundername: Institute for Engineering in Medicine (University of Minnesota) |
GroupedDBID | --- 00X 0R~ 0YH 29J 36B 4.4 5GY 5RE AALUX AAPXX AATTQ ABBKH ABDBF ABLKL ABPTK ACFUF ACGEJ ACGFS ADBBV ADCVX ADFCX ADRBQ ADXPE AENEX AEYQI AFKVX AIJEM AJWEG ALIIL ALMA_UNASSIGNED_HOLDINGS BABNJ BCNDV BLEHA BOHLJ CCCUG CS3 DKSSO DU5 EAP EAS EBB EBC EBD EBO EBS EBX EHN EJD EMB EMK EMOBN EPL EPT ESX F5P GROUPED_DOAJ H13 HZ~ I-F J.N KRBQP KSSTO KTTOD KWAYT L7B M4Z O9- OK1 P2P QZIEQ Q~Q SV3 TFDNU TFL TFW TH9 TUS V1S ZA5 ~1N 53G 5VS AALIY ABUPF AGYJP AWYRJ BRMBE CAG CGR COF CUY CVF CYYVM CZDIS DRXRE ECM EIF M44 NPM QQXMO TDBHL UDS ZGI AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c479t-1b6a71a358d73fe6dc6478caae78afec7e0d9c1290f6c88e8b4c5439b642b1c43 |
IEDL.DBID | DOA |
ISSN | 0265-6736 |
IngestDate | Tue Oct 22 15:13:05 EDT 2024 Tue Aug 27 04:54:28 EDT 2024 Fri Aug 23 01:05:04 EDT 2024 Tue Aug 27 13:45:46 EDT 2024 Tue Jun 13 19:52:09 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | CD8 T cell T cell activation proliferation B16 protein denaturation melanoma antigen western blot viability dendritic cells protein release immune response cancer Focal therapy antigen presenting cells |
Language | English |
License | open-access: http://creativecommons.org/licenses/by/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c479t-1b6a71a358d73fe6dc6478caae78afec7e0d9c1290f6c88e8b4c5439b642b1c43 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-8190-1067 |
OpenAccessLink | https://doaj.org/article/f2ef4e000aa0489eb5aa419e6de38589 |
PMID | 30676126 |
PQID | 2179478377 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2179478377 informaworld_taylorfrancis_310_1080_02656736_2018_1539253 doaj_primary_oai_doaj_org_article_f2ef4e000aa0489eb5aa419e6de38589 pubmed_primary_30676126 crossref_primary_10_1080_02656736_2018_1539253 |
PublicationCentury | 2000 |
PublicationDate | 1/1/2019 2019-00-00 2019-01-01 20190101 |
PublicationDateYYYYMMDD | 2019-01-01 |
PublicationDate_xml | – month: 01 year: 2019 text: 1/1/2019 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | International journal of hyperthermia |
PublicationTitleAlternate | Int J Hyperthermia |
PublicationYear | 2019 |
Publisher | Taylor & Francis Taylor & Francis Group |
Publisher_xml | – name: Taylor & Francis – name: Taylor & Francis Group |
References | CIT0030 CIT0032 CIT0031 CIT0034 CIT0033 CIT0036 CIT0035 CIT0038 CIT0037 CIT0039 Fiege JK (CIT0054) 2016; 197 CIT0041 CIT0040 CIT0043 Watkins SK (CIT0050) 2012; 64 Michalek MT (CIT0057) 1996; 157 CIT0042 CIT0001 CIT0045 CIT0003 CIT0047 CIT0002 CIT0046 CIT0005 CIT0049 CIT0004 CIT0048 CIT0007 CIT0006 CIT0009 CIT0008 CIT0052 CIT0010 Skitzki JJ (CIT0021) 2009; 10 CIT0053 CIT0012 CIT0011 CIT0055 Dick LR (CIT0056) 1994; 152 CIT0014 CIT0058 CIT0013 CIT0016 CIT0015 CIT0059 CIT0018 CIT0017 Ya Z (CIT0044) 2001 CIT0019 CIT0061 CIT0060 Zhu ZQ (CIT0051) 2015; 195 CIT0062 CIT0020 CIT0023 CIT0022 CIT0025 CIT0024 CIT0027 CIT0026 CIT0029 CIT0028 |
References_xml | – ident: CIT0029 doi: 10.1158/1078-0432.CCR-04-2422 – ident: CIT0047 doi: 10.1038/nprot.2015.024 – ident: CIT0006 doi: 10.1038/nrc3672 – ident: CIT0012 doi: 10.1007/s10439-017-1932-3 – ident: CIT0025 doi: 10.1158/1078-0432.CCR-09-0110 – ident: CIT0028 doi: 10.1148/radiol.13120249 – ident: CIT0048 doi: 10.1016/j.bbabio.2007.06.004 – ident: CIT0062 doi: 10.1007/978-3-319-55113-5_17 – ident: CIT0017 doi: 10.1038/nrurol.2010.142 – ident: CIT0011 doi: 10.1115/1.4039375 – ident: CIT0020 doi: 10.1016/j.canlet.2008.05.026 – ident: CIT0035 – ident: CIT0030 doi: 10.1038/sj.bjc.6603341 – ident: CIT0055 doi: 10.1038/nri1372 – ident: CIT0040 doi: 10.1016/j.semcancer.2007.06.008 – ident: CIT0001 doi: 10.1080/02656730500271692 – ident: CIT0045 doi: 10.1016/bs.ai.2015.12.004 – ident: CIT0043 doi: 10.1073/pnas.0915174107 – ident: CIT0023 doi: 10.1245/s10434-009-0846-1 – volume: 64 start-page: e3952 year: 2012 ident: CIT0050 publication-title: J Vis Exp contributor: fullname: Watkins SK – volume: 10 start-page: 550 year: 2009 ident: CIT0021 publication-title: Curr Opin Invest Drugs contributor: fullname: Skitzki JJ – ident: CIT0003 doi: 10.1016/j.jvir.2014.01.028 – ident: CIT0052 doi: 10.4049/jimmunol.179.11.7577 – ident: CIT0002 doi: 10.1109/TBME.2014.2314357 – ident: CIT0058 doi: 10.1007/s13277-015-4126-3 – ident: CIT0032 – volume: 157 start-page: 617 year: 1996 ident: CIT0057 publication-title: J Immunol doi: 10.4049/jimmunol.157.2.617 contributor: fullname: Michalek MT – ident: CIT0018 doi: 10.2214/ajr.174.2.1740323 – ident: CIT0005 doi: 10.1007/s00270-007-9208-1 – ident: CIT0022 doi: 10.1016/j.cryobiol.2008.10.126 – ident: CIT0053 doi: 10.4049/jimmunol.1300107 – ident: CIT0046 doi: 10.1016/j.bbamem.2013.01.014 – volume: 197 start-page: 2079 year: 2016 ident: CIT0054 publication-title: JI contributor: fullname: Fiege JK – ident: CIT0014 doi: 10.7717/peerj.2810 – ident: CIT0037 doi: 10.1016/j.immuni.2013.07.012 – volume-title: Mouse model for pre-clinical study of human cancer immunotherapy. Current protocols in immunology year: 2001 ident: CIT0044 contributor: fullname: Ya Z – volume: 152 start-page: 3884 year: 1994 ident: CIT0056 publication-title: J Immunol doi: 10.4049/jimmunol.152.8.3884 contributor: fullname: Dick LR – ident: CIT0019 doi: 10.1016/S0140-6736(10)62307-0 – ident: CIT0015 doi: 10.1038/srep27136 – ident: CIT0036 doi: 10.1016/j.coi.2013.02.009 – ident: CIT0013 doi: 10.1016/j.cryobiol.2016.09.063 – ident: CIT0039 doi: 10.1172/jci.insight.90521 – ident: CIT0033 – ident: CIT0008 doi: 10.1080/02656730310001637343 – ident: CIT0038 doi: 10.1038/nature10673 – ident: CIT0026 doi: 10.1080/02656730902976807 – ident: CIT0042 doi: 10.1038/nri3339 – ident: CIT0049 doi: 10.1114/B:ABME.0000042226.97347.de – ident: CIT0004 doi: 10.1148/radiol.10081634 – ident: CIT0060 doi: 10.1016/j.diii.2018.02.002 – ident: CIT0024 doi: 10.1021/mp300505w – ident: CIT0027 doi: 10.1158/0008-5472.CAN-06-0206 – ident: CIT0010 doi: 10.1109/TBME.2014.2367543 – ident: CIT0016 doi: 10.1038/sj.jid.5700777 – volume: 195 start-page: 3482 year: 2015 ident: CIT0051 publication-title: JI contributor: fullname: Zhu ZQ – ident: CIT0034 – ident: CIT0007 doi: 10.1016/j.vaccine.2011.11.080 – ident: CIT0009 doi: 10.1111/j.1464-410X.2005.05502.x – ident: CIT0031 doi: 10.1158/0008-5472.CAN-11-1782 – ident: CIT0041 doi: 10.1007/s00262-016-1891-9 – ident: CIT0061 doi: 10.1016/j.ccell.2018.03.008 – ident: CIT0059 doi: 10.1016/S1470-2045(15)00007-8 |
SSID | ssj0004527 |
Score | 2.5316336 |
Snippet | Focal thermal therapy (Heat), cryosurgery (Cryo) and irreversible electroporation (IRE) are increasingly used to treat cancer. However, local recurrence and... |
SourceID | doaj proquest crossref pubmed informaworld |
SourceType | Open Website Aggregation Database Index Database Publisher |
StartPage | 130 |
SubjectTerms | Animals antigen antigen presenting cells Antigens, Neoplasm - metabolism b16 cancer CD8 T cell CD8-Positive T-Lymphocytes - immunology dendritic cells Focal therapy Humans immune response melanoma Mice Mice, Transgenic Neoplasms - immunology proliferation protein denaturation protein release T cell activation viability western blot |
SummonAdditionalLinks | – databaseName: Taylor & Francis Open Access dbid: 0YH link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8QwEA4-QLyIb9cXEbxW-8jzqKIsgp4U9BSSNPG2ld3uwX_vTNPKKogHjy2lTWcyk5nJN18IOS-YB3-Y-0wJETPGsVm50kUWhaiDEiFKjw3OD49i_MzuX_iAJpz1sErMoWMiiuh8NRq3dbMBEXcJaQNHOBICs9QFmKwuebVMVksIvXGq56_jRcJwmcosvEO5D008v73m2_LUsfj_4DD9PRLtVqS7TbLRh5L0Kul-iyyFyTZZe-g3y3fIywLXIH2iWKKn0wSJDbRtqEeFTymIFhk5Z9R9UPCF4DhoE2nENY4udGdRSJzrhO_aJc93t08346w_SCHzTOo2K5ywsrAVV7WsYhC1xw5Tb22QysbgZchr7bEiFYVXKijHPIdIxUFy4grPqj2yMmkm4YBQyNZiWYNjiMozHysr61y4WmueR-mYHZGLQX7mPfFlmGKgIe0FblDgphf4iFyjlL8eRrrr7kYzfTO99ZhYhsgCqNNa8Dg6OG4tKzT8ScCNTT0ielFHpu2qHTEdTWKqPwZwNijUgGmhMuwkNPOZKdFZScjg5YjsJ01_DRMzLQgOxeE_vnxE1uFSp4LOMVlpp_NwAiFO6067SfwJdyvv3w priority: 102 providerName: Taylor & Francis |
Title | Engineering T cell response to cancer antigens by choice of focal therapeutic conditions |
URI | https://www.tandfonline.com/doi/abs/10.1080/02656736.2018.1539253 https://www.ncbi.nlm.nih.gov/pubmed/30676126 https://search.proquest.com/docview/2179478377 https://doaj.org/article/f2ef4e000aa0489eb5aa419e6de38589 |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07T8MwELagA2JBvCmPykisgaTxcwREVSHBBFKZLNuxxxaVdODfcxcnpSChLqxWFJ2-Lz7fXe4-E3JVMA_-MPeZEiJmjOOwcqmLLApRBSVClB4HnJ-exfiVPU74ZOWqL-wJS_LACbibOAyRBdi41sLHpoPj1rJCB3gV_tNKo3sF75Kpb51wmaorvGlu72Z3UFUb1nAJ27rUNWx4PeTlj1OpEe__JV36dwDaHESjXbLTRpD0Nlm-RzbCdJ9sPbX_yA_IZEVikL5QrMzTeeqEDbSeUY88zykgikKcH9R9UnCB4C_oLNKIRxtdGcqikC9Xqa3rkLyOHl7ux1l7f0LmmdR1VjhhZWFLripZRkDM42CptzZIZWPwMuSV9liIisIrFZRjnkOA4iAncYVn5RHpTWfTcEIoJGlxWIE_iMozH0srq1y4SmueR-mY7ZPrDj_znmQyTNGpj7aAGwTctID3yR2ivHwYVa6bBeDetNybddz3iV7lyNRNkSOmG0lMucaAy45QAzsKybDTMFt8mCH6KAmJu-yT48T00kxMsCAmFKf_Yf4Z2QaLdCronJNePV-ECwhxajcgm_nbeNB801-GlPRl |
link.rule.ids | 315,786,790,870,2115,4043,27533,27954,27955,27956,59496,59497 |
linkProvider | Directory of Open Access Journals |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB6VVipcUEuhXR7FSFxTko2fR0Ctlrbb01ZaTpbt2Nw2aJse-PfMxEkVkCoOXJPIcWYy4_nGM58BPlY8oD8sQ6GlTAUX1Kxcm6pIUjZRy5hUoAbn5Y1c3PLLtVhPemGorJIwdMpEEb2vJuOmZPRYEvcJcYOgeiSqzNJnaLNmLuonsCcMNwTAyu-LKWO4ynkW0Ze5j108jw3zx_rU0_j_RWL6eCjaL0kXB_B8iCXZ56z8Q9iJmxewvxx2y49gPSEbZCtGOXq2zTWxkXUtC6TxLUPZEiXnHfO_GDpD9BysTSzRIscm7VkMkXOTC7xewu3F-errohhOUigCV6YrKi-dqlwtdKPqFGUTqMU0OBeVdikGFcvGBEpJJRm0jtrzIDBU8YhOfBV4_Qp2N-0mngBDuJbmDXqGpAMPqXaqKaVvjBFlUp67GZyN8rM_M2GGrUYe0kHglgRuB4HP4AtJ-eFh4rvuL7TbH3YwH5vmMfGI6nQOXY6JXjjHK4NfEmln08zATHVkuz7dkfLZJLb-xwQ-jAq1aFukDLeJ7f2dnZO3Ugjh1QyOs6YfpklQC6ND-fo_3vweni5Wy2t7_e3m6g08w1smZ3fewm63vY_vMN7p_Gn_Q_8GkqfzVQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZKK1VcEJTX8miNxDUl2fh55LXatrTi0ErlZPk13DbVbnrg3zMTJ9WCVHHgmkSJM-MZz4y_-czY-0ZE9Id1rIxSUAlJzcqtbSpQKmWjMuhIDc7nF2p5JU6v5YQm3IywSsqhoRBFDL6ajPsmwYSI-4BpgyQ4EgGzzDGarJ3L9gHbk1ZYmuT1j-U2YbguZRY5oNynJp77XvPH8jSw-P_FYXp_JDqsSIvH7NEYSvKPRfdP2E5eHbD983Gz_Cm73uIa5JecSvR8XSCxmfcdj6TwNUfREiPnhodfHH0hOg7eAQda4_hWdxbHxDkVfNczdrX4evl5WY0HKVRRaNtXTVBeN76VJukWskqROkyj91kbDznqXCcbqSIFKhqTTRBRYqQSMDkJTRTtc7a76lb5JeOYrcE8oWMAE0WE1utUq5CslTXoIPyMHU_yczeFL8M1Ew3pKHBHAnejwGfsE0n57mGiux4udOufbrQeB_MMIqM6vUePY3OQ3ovG4p9k2ti0M2a3deT6odoB5WgS1_5jAO8mhTo0LVKGX-XuduPm5Kw0ZvB6xl4UTd8NkzItDA7Vq__48hHb__5l4b6dXJy9Zg_xji21nTdst1_f5rcY7fThcJjPvwEQdvJ- |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Engineering+T+cell+response+to+cancer+antigens+by+choice+of+focal+therapeutic+conditions&rft.jtitle=International+journal+of+hyperthermia&rft.au=Shao%2C+Qi&rft.au=O%27Flanagan%2C+Stephen&rft.au=Lam%2C+Tiffany&rft.au=Roy%2C+Priyatanu&rft.date=2019&rft.eissn=1464-5157&rft.volume=36&rft.issue=1&rft.spage=130&rft_id=info:doi/10.1080%2F02656736.2018.1539253&rft_id=info%3Apmid%2F30676126&rft.externalDocID=30676126 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0265-6736&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0265-6736&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0265-6736&client=summon |